Eli Lilly: Antibody combo works best on COVID-19 variants
The Indianapolis-based company is asking U.S. regulators to revoke their emergency authorization for the use of bamlanivimab alone, in favor of its combination with another drug.
Eli Lilly and Co.
Articles
Proposed Indiana voting law change faces corporate criticism
Stephen Fry, Eli Lilly and Co.’s senior vice president for human resources and diversity, told a legislative committee Tuesday that the company believed the bill aimed at reducing voter fraud wasn’t needed.
Lilly exec created hostile work environment for women, former lobbyist claims in suit
Sonya Elling filed suit Friday in federal court against the drugmaker, alleging that Leigh Ann Pusey, senior vice president for corporate affairs and communications, precluded her from engaging with members of Congress because she was “not a cute, young thing.”
FDA panel rejects Pfizer/Lilly arthritis drug tanezumab as too risky
The expert panel for the Food and Drug Administration voted 19-1 that the drug’s modest benefits don’t outweigh its considerable risks, even with proposed measures to restrict who gets the medicine.
Lilly’s Alzheimer’s drug shows modest benefit in mid-stage trial
Eli Lilly and Co. on Saturday morning presented highly anticipated details from a mid-stage study showing that its experimental drug slowed Alzheimer’s disease progression over about 18 months.
Insider alleges Lilly blocked her efforts to sound alarms about U.S. drug factory
Eli Lilly and Co. told Reuters news agency that it is working closely with the FDA to address concerns about the factory in Branchburg, New Jersey, which makes Trulicity.
Lilly signs deal to sell $210M worth of COVID-19 antibodies to U.S. government
The Indianapolis-based drugmaker said it will begin shipping the additional doses immediately to the federal government, which controls distribution of the drugs.
Indiana Senate panel advances bill that would pass along drug rebates to consumers
The bill pitted the two largest companies headquartered in Indianapolis—drugmaker Eli Lilly and Co. and health insurer Anthem Inc.—on opposite sides of the issue.
Lilly’s flush pipeline makes it Wall Street darling
If you follow the daily drumbeat of news emanating out of Lilly Corporate Center, you might not grasp how phenomenally well the company is poised to perform in the coming years.
Former Lilly CFO Smiley to lose millions of dollars under separation agreement
Josh Smiley, Lilly’s CFO since 2018, resigned from the company after the drugmaker said he had engaged in a improper personal relationship with an employee.
Lilly’s COVID-19 antibody combo gets U.S. emergency authorization
The combo treatment is the second COVID-19 antibody therapy from the Indianapolis-based drugmaker to gain an emergency authorization from the FDA.
Lilly CFO resigns after ‘inappropriate personal relationship’ with employee
Joshua Smiley, who was Lilly’s second-highest-paid employee, was named CFO in January 2018. Lilly said Smiley also engaged in “inappropriate personal communications” with other employees.
Hope at Lilly after years of Alzheimer’s failures
Lilly has spent three decades and more than $3 billion trying to find a way to treat Alzheimer’s disease. Its latest drug, donanemab, finally shows real promise.
Lilly quarterly profit surges, helped by new COVID-19 treatment
The antibody treatment bamlanivimab was Lilly’s second-highest selling product in the final quarter of 2020, trailing only the popular diabetes drug Trulicity.
Eli Lilly, Glaxo join forces to test COVID-19 antibody cocktail
GlaxoSmithKline and partner Vir Biotechnology Inc. have teamed up with Indianapolis-based Eli Lilly and Co. to test a combination of their COVID-19 antibody treatments to see whether they can better combat the virus and its variants together.
Lilly to help Dutch biotech develop cancer therapies in deal worth up to $1.6B
Merus N.V. specializes is so-called CD3 engaging T-cell therapies, a growing area of cancer research, based on immunotherapy, or using the immune system’s T cells to find and shrink tumors
Lilly invests $30M in new fund for minority health-care startups
The Indianapolis-based drugmaker said people from minority communities are frequently “unseen” by the U.S. health care system.
Lilly suspends contributions to 4 Indiana Congress members over certification votes
Several other Indiana companies also say they are suspending contributions to all candidates or are taking a close look at the matter.
In midst of pandemic, drugmakers raise prices on hundreds of prescription drugs
So far this month, drugmakers have hiked prices on 636 drugs, according to research by GoodRx, which tracks prescription drug prices and offer a mobile app to help consumers find the lowest prices on hundreds of drugs.
Lilly shares surge after its potential Alzheimer’s drug slows cognitive decline
The experimental drug, donanemab, could be a huge breakthrough for Lilly, which has spent billions of dollars over 30 years researching treatments for Alzheimer’s disease, only to see them fall short in clinical trials.